1. Introduction {#sec1}
===============

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the axial skeleton, causing characteristics inflammatory back pain, which can lead to structural and functional impairments. Asymmetric peripheral arthritis is present in about 20--40% of patients with AS \[[@B1]\]. In Europe, estimates of prevalence of ankylosing spondylitis vary by tenfold from 0.08% to 0.86% \[[@B2]--[@B4]\]. The direct costs of AS are substantial. In Europe, the annual total direct costs per patient have been estimated at €1,800 to €2,800 \[[@B5]\]. The introduction of antitumour necrosis factor alpha (anti-TNF*α*) agents has increased the direct cost of AS \[[@B6]\].

The first-line treatment of AS is nonsteroidal anti-inflammatory drugs (NSAIDs) \[[@B7]--[@B9]\]. Patients with severe disease refractory to NSAIDs are eligible for anti-TNF*α* agents \[[@B10]\]. The nonselective NSAIDs (nsNSAIDs) have been associated with an increased risk of gastrointestinal (GI) adverse events such as ulcers and GI bleeding because of their inhibition of the gastroprotective COX-1 isoform. COX-2 selective inhibitors were developed with reduced GI toxicity when compared with nonselective NSAIDs. Etoricoxib and celecoxib have been demonstrated to have a superior upper gastrointestinal (GI) safety profile \[[@B11]--[@B14]\]. The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long Term) program demonstrated the risk of cardiovascular (CV) events with etoricoxib (60 mg/d and 90 mg/d) comparable to diclofenac (75 mg bid and 50 mg tid) \[[@B15]\]. On the efficacy side, etoricoxib has been shown, at doses of 90 mg and 120 mg, to be superior compared to naproxen 1000 mg in the treatment of AS \[[@B16]\]. Celecoxib (200 mg and 400 mg) showed comparable efficacy to diclofenac (150 mg) \[[@B17]\].

Given the economic burden of AS, a cost-effectiveness analysis of interventions for AS is warranted. The objective of this study was to evaluate the cost-effectiveness of etoricoxib (90 mg) compared to celecoxib (200 and 400 mg), diclofenac (150 mg), and naproxen (1000 mg) in the treatment of patients with AS in Norway. Analyses were performed from the health care perspective.

2. Methods {#sec2}
==========

In the present economic evaluation, a comprehensive decision Bayesian modelling approach was used which integrates evidence synthesis and parameter estimation for efficacy and safety with cost-effectiveness modeling in a single unified framework \[[@B18]\].

2.1. Markov Model Description {#sec2.1}
-----------------------------

A previously published Markov-state transition model was used to estimate the cost-effectiveness of etoricoxib versus celecoxib and nsNSAIDs in the treatment of AS patients requiring daily NSAID treatment \[[@B50]\]. The model consisted of eight health states reflecting treatment received: (1) "initial NSAID" (etoricoxib, celecoxib, or nsNSAIDs, depending on intervention arm of the model), (2) "initial NSAID with proton-pump inhibitor (PPI)," (3) alternative nsNSAIDs with PPI, (4) alternative nsNSAID with PPI and aspirin, (5) alternative nsNSAID, (6) anti-TNF*α* treatment, (7) discontinued anti-TNF*α* treatment, and (8) death. All patients start in health state 1. Transitions from state to state were determined by lack of treatment efficacy, and the different types of events as presented in [Table 1](#tab1){ref-type="table"}. [Figure 1](#fig1){ref-type="fig"} presents the different types of cost generating GI, CV, and other events relevant to each Markov cycle.

For each health state, utilities were assigned based on the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \[[@B19]\]. Over time, BASFI will worsen thereby decreasing utilities. Disutilities were assigned based on occurrence of adverse events. Drug acquisition costs, and cost due to adverse events were taken into account.

The model was developed with a cycle length of 1 year. The model followed individuals for a maximum of 30 cycles (30 years) as by this time the majority of individuals had reached the absorbing state (i.e., death).

2.2. Source Data {#sec2.2}
----------------

### 2.2.1. Efficacy: BASFI, BASDAI, and Discontinuation due to Lack of Efficacy {#sec2.2.1}

The efficacy of etoricoxib, celecoxib, diclofenac, or naproxen in AS regarding BASFI, BASDAI, and discontinuation was obtained from a previously performed systematic review and Bayesian mixed treatment comparison (MTC) of randomized controlled trials using noninformative prior distributions \[[@B50], [@B20], [@B21]\]. In [Table 2](#tab2){ref-type="table"} the individual study results are presented. In [Table 3](#tab3){ref-type="table"}, the results of the MTC as used in the cost-effectiveness analysis are presented.

For the model analysis, the expected change from baseline (CFB) estimates for BASFI and BASDAI by treatment were subtracted from background BASFI and BASDAI values which develop over time. Over time, an increase in BASFI of 0.5 (scale 0--100) per annum was assumed \[[@B6], [@B19]\]. It was assumed that background BASDAI scores remained stable over time \[[@B16], [@B22], [@B23]\]. For patients who continue responding to treatment, it is assumed that their treatment effect regarding BASFI and BASDAI (i.e., the CFB scores) remain constant over time. Patients who switched to another nsNSAIDs were assumed to have the average treatment effect of diclofenac and naproxen as obtained from the MTC. For patients that switched to anti-TNF*α*, a treatment effect of 23 points and 19 points was used for BASFI and BASDAI, respectively.

It was assumed that 10% withdraw from anti-TNF*α* each year \[[@B19], [@B24]\]. For patients who withdraw from anti-TNF*α* treatment BASDAI, and BASFI measurements revert back to baseline values as reported by Ara et al. \[[@B19]\].

### 2.2.2. Safety {#sec2.2.2}

An overview of all event-related parameters is presented in [Table 3](#tab3){ref-type="table"}. Incidence rates of an upper GI perforation, ulcer, or bleeding (PUB) for etoricoxib, celecoxib, and the nsNSAIDs were estimated with an indirect comparison of the relative incidence rates versus placebo as reported by Ramey et al. (OA, RA, and AS patients) and Silverstein et al. (OA and RA patients) \[[@B11], [@B14], [@B50]\]. Incidence rates for suspected PUBs were calculated by subtracting the PUBS from all-investigator-reported PUBs by Ramey et al. \[[@B11]\]. Rates of minor GI symptoms were based on discontinuations due to clinical GI events in the MEDAL programme \[[@B27]\]. Except for PUBs, the rates for other upper GI events with etoricoxib were also used for the celecoxib arm of the model. The probabilities of treatment of GI events were based on Moore et al. \[[@B28]\].

The incidence of a thrombotic CV event with etoricoxib, diclofenac, and naproxen were obtained by performing an indirect comparison of the results from the MEDAL programme by Cannon et al. and the relative incidence rate of etoricoxib versus naproxen from a meta-analysis of thrombotic CV events in 12 phase II-IV clinical trials \[[@B15], [@B50], [@B29]\]. Rates for etoricoxib were also used for the celecoxib arm of the model. The occurrence of edema, hypertension, coronary heart failure, hepatic adverse events, and renal events were obtained from the MEDAL programme as well \[[@B15]\]. For anti-TNF*α* treatment, and treatment after anti-TNF*α*, no adverse events were taken into consideration.

The adverse event rate for second-line nsNSAID therapy was assumed to be equal to the average of those obtained for diclofenac and naproxen, with the exception of the incidence of an upper GI event in a patient receiving nsNSAID plus PPI therapy, which was assumed to be reduced by 40% \[[@B28]\]. The GI and CV risk for a patient who switched to nsNSAID plus aspirin and PPI was assumed to be comparable to that for nsNSAID alone.

### 2.2.3. Mortality {#sec2.2.3}

The case-fatality of a UGI PUB or LGI Bleed was 3.6% \[[@B28], [@B30]\]. A 13% case-fatality for a CV event was used for etoricoxib and celecoxib, and 12.8% case-fatality for nsNSAIDs \[[@B15]\]. For patients not experiencing GI or CV adverse events, a Norwegian annual age-dependent mortality was used, as obtained from the life tables for Norway \[[@B31]\]. For the evaluation, an AS population with an average age of 45 was assumed (base-case scenario) \[[@B16]\].

### 2.2.4. Utilities {#sec2.2.4}

Utilities reflect the preference for a certain health state and are measured on 0-1 scale. A value of 1 reflects perfect health and 0 represents death. By summarizing the utility value over time, quality adjusted life years (QALYs) are created. Life years were transformed into QALYs using a relation between utility (EQ-5d) and BASFI and BASDAI as derived by Ara et al. \[[@B19]\]: Utility = 0.923 − 0.004\*BASFI − 0.004\*BASDAI. Utility loss associated with adverse events was obtained from the literature \[[@B28], [@B32]--[@B35]\].

### 2.2.5. Costs {#sec2.2.5}

Annual drug acquisition costs were calculated based on the most commonly prescribed drug within a drug class and obtained from the Norwegian Medicines Agency (NoMA September 2007). For anti-TNF treatment, annual costs of etanercept were used. For each type of GI event, numbers of units of health care resource use were assigned and respective unit costs applied to all healthcare resources to calculate the cost per event. The key cost items for GI events included costs of treatment (drugs and dispensing), GP consultations, investigations, inpatient days, and surgery. Costs of thrombotic CV events were weighted according to rates in the MEDAL study. All costs of adverse events were limited to the first year. Cost for the other adverse events (i.e., edema, hypertension, hepatic, and renal) were not taken into consideration. Drug costs related to adverse events were obtained from NoMA (September 2007); costs related to GP visits were obtained from the Norwegian Medical Association (July 2007), and inpatient costs related to events were obtained from the DRG price list \[[@B36]\]. All costs were expressed in 2007 Norwegian kroner (NOK).

2.3. Estimating Model Outcomes {#sec2.3}
------------------------------

Given the Markov state-transition model structure, the source data were combined and translated into the following outcomes: quality adjusted life years, drug acquisition costs, costs of adverse events, total costs, and net monetary benefit (NMB) calculated as QALYs multiplied with a willingness-to pay ratio (WTP) minus costs. WTP is the amount that decision makers are willing-to pay per additional QALY gained. Effects and costs were all discounted at 4% in the base-case scenario.

Since the model was fully probabilistic, outcomes were estimated with MCMC simulation using WinBUGS v 1.4. For each iteration of the model, new parameter values were sampled from the estimated (posterior) or defined distributions for efficacy, safety, and costs (see [Table 3](#tab3){ref-type="table"}). The model was evaluated by averaging output values over many iterations (i.e., 10.000), allowing uncertainty in model parameters to be accounted for. For each iteration, the QALYs and cost accrued for each cycle were calculated for each of the treatments according to Sonnenberg and Beck \[[@B37]\]. At the end of each iteration, the cumulative QALYs and costs over the cycles were obtained by summing the results over all cycles. Next, the incremental cost, incremental QALYs, and incremental cost-effectiveness ratio (ICER = incremental costs/incremental QALYs) of etoricoxib versus the other interventions were evaluated. The probability of cost-effectiveness was expressed with cost-effectiveness acceptability curves, calculated as the number of iterations out of the total number of iterations for which the NMB was greatest for a given treatment out of all 4 treatments. Furthermore, analysis were performed to identify the impact of uncertainty in the source data on the uncertainty in the QALYs, costs, and NMB estimates.

In the base-case scenario, etoricoxib (90 mg) was compared with celecoxib (200 mg & 400 mg), diclofenac (150 mg), and naproxen (1000 mg). In alternative analyses, the following scenarios were evaluated: (1) celecoxib 200 mg was used instead of celecoxib 200 mg/400 mg, (2) only GI events, (3) only CV events, (4) no adverse events, (5) no discounting on costs and effects, (6) 8% discounting on costs and effects, (7) stable BASFI over time, and (8) assuming an age of 20 years, and (9) anti-TNF*α* costs excluded. For each scenario uncertainty in input parameters was taken into consideration, as outlined above.

3. Results {#sec3}
==========

3.1. Base-Case Scenario {#sec3.1}
-----------------------

In [Table 4](#tab4){ref-type="table"}, the results of the base-case scenario are presented for 1 year, 5 years, and 30 years of follow-up. There was more than 98% probability that etoricoxib resulted in higher expected QALYs than the other interventions of interest.

Drug costs are expected to be the highest with celecoxib (200 & 400 mg) followed by etoricoxib (90 mg). The nsNSAIDs result in the lowest drug costs. After 5 years, however, the lowest drug costs can be expected for the patients for whom treatment was initiated with etoricoxib due to the higher probability of staying on initial therapy and not switching to the far more expensive anti-TNF*α* treatment. After 30 years, the difference favoring etoricoxib was even greater.

Relative to a patient starting with nsNSAIDs, the costs due to GI events were lower for a patient starting with etoricoxib or celecoxib as a result of a reduced risk of treatment-requiring GI events. After 30 years, the GI-related costs with etoricoxib were higher than with celecoxib because this latter group of patients switched quicker to anti-TNF*α*, which is not associated with GI events. Until 5 years, costs related to thrombotic CV events were similar with etoricoxib, celecoxib, and diclofenac, and slightly higher than with naproxen. For the same reason as the GI-related costs, the CV-related costs with etoricoxib were higher than with celecoxib and diclofenac at 30 years of followup. Overall, naproxen resulted in the lowest cost at 1 year; however, at 5 years and beyond, etoricoxib resulted in the lowest direct costs of the four alternatives; at 5 year, there is a \>96% probability that the lowest costs are obtained with etoricoxib. This increased to \>99% at 30 years.

In [Table 5](#tab5){ref-type="table"}, the difference in costs and QALYs of etoricoxib relative to the other interventions is presented. Given the more favourable outcomes regarding costs and QALYs with etoricoxib after 5 years of followup, etoricoxib is considered an economically dominant intervention. At 1 year, etoricoxib is economically dominant over celecoxib. The incremental cost-utility ratio (ICER) of etoricoxib relative to diclofenac and naproxen at 1 year was 59,221 NOK and 107,256 NOK, respectively. In [Figure 2](#fig2){ref-type="fig"}, the probability of cost-effectiveness for the different interventions at different willingness-to-pay (WTP) ratios are presented. For a WTP 200,000 NOK per QALY there is an 85% probability that etoricoxib is the most cost-effective intervention at 1 year. This increased to more than 96% for WTP of 500,000 NOK and higher. At 5 and 30 years, there is a more than 99% probability that etoricoxib is the most cost-effective intervention. [Figure 3](#fig3){ref-type="fig"} provides an overview which of the parameters have the greatest impact on (uncertainty) in model outcomes.

### 3.1.1. Alternative Scenarios {#sec3.1.1}

When celecoxib 200 mg was used as a comparator instead of celecoxib 200 mg & 400 mg combined, etoricoxib was no longer economically dominant at 1 year. Etoricoxib is 1,322 NOK more expensive. Given the QALY gain of 0.07, this translates into a cost per QALY of 17,882 NOK, a cost-effective result.

Scenarios where (1) only GI events were included as adverse events, (2) only CV events were included as adverse events, (3) no adverse events were included, (4) no discounting was applied, (5) 8% discounting was applied, (6) BASFI was assumed to be stable over time, and (7) assuming an average age of 20 years provided comparable cost-effectiveness results as the base-case analysis. Only for the scenario where anti-TNF*α* costs were set to zero, etoricoxib was no longer dominant. However, etoricoxib can still be considered cost-effective, independent of the time horizon (see [Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

The economic evaluation demonstrated that etoricoxib (90 mg) is an economically superior treatment of AS to celecoxib (200 & 400 mg), diclofenac (150 mg), and naproxen (1000 mg) for both QALY gains and cost savings for a time horizon longer than 5 years. For a 1-year time horizon, etoricoxib is associated with greater costs than diclofenac (150 mg) and naproxen (1000 mg), but can still be considered cost effective.

In addition to drug acquisition costs for the NSAIDs, also costs for anti-TNF*α* treatment after failure on NSAIDs were taken into consideration. Given the model structure we opted for, the average duration on any NSAID was estimated to be 11.2 years (95% CrI 9.0--13.2) for the patients starting with etoricoxib, 7.8 (6.8--9.0) years with celecoxib, 8.3 (6.8--10.1) years with diclofenac, and 8.4 (6.9--10.2) years with naproxen. These differences explain the savings regarding drug acquisition observed when initiating treatment with etoricoxib over the other treatment strategies observed at the 5,- and 30-year time horizon. However, when the anti-TNF*α* acquisition costs are taken out of the picture, etoricoxib is still economically more favorable than celecoxib, diclofenac, or naproxen (see [Table 6](#tab6){ref-type="table"}).

For the current economic evaluation, a comprehensive decision modeling approach was used. With this approach, an indirect comparison of efficacy and safety estimates were integrated with cost-effectiveness analysis in a single framework \[[@B18]\]. The advantage of this approach is that no assumptions were made regarding the uncertainty distributions used for sensitivity analysis; the Bayesian posterior uncertainty distributions of the treatment effect and GI and CV events as obtained from the MTC were directly propagated through the Markov model. The most important factor in the cost-effectiveness analysis was the probability of discontinuation as estimated with the MTC (see [Figure 3](#fig3){ref-type="fig"})

The etoricoxib GI safety data as used in the analysis were obtained from clinical trials in OA, RA, AS, and chronic low back pain patients \[[@B11]\]; the celecoxib GI safety data were obtained from the CLASS study \[[@B14]\]. These data were assumed applicable for AS. It could be argued that AS patients are likely younger than the average patient in the GI meta-analysis and, therefore, have a lower GI risk. However, AS patients often receive higher nsNSAID doses than patients with other arthritic conditions, thereby increasing their risk for GI events. Risk estimates of CV events were based on the MEDAL programme comparing etoricoxib with diclofenac among OA and RA patients and a meta-analysis of 12 phase II-IV clinical trials comparing etoricoxib with naproxen, among OA, RA, AS, and chronic low back pain patients \[[@B15], [@B29]\]. As AS patients are on average younger than patients in the MEDAL programme and the meta-analysis, it can be argued that the risk for CV events might have been overestimated in the model.

In the model, the risk for a second CV event was set to be the same as before the CV event, assuming that the increased CV risk due to the history of a CV event was counterbalanced by adding aspirin to the NSAID. However, the history of a CV event might have a bigger impact than the protective effect by aspirin, which would imply an underestimation of the risk of CV events in the model, and, therefore, an underestimation of the costs due to CV events. The effect on the difference in costs, however, would be limited because the underestimation applies to both treatment initiated with etoricoxib and nsNSAIDs.

Costs associated with severity of AS (i.e., GP visits, specialist visits, paramedical visits, hospitalization, technical examinations, adaptations and aids) were not included in the analysis. For the UK, Botteman et al. showed that each incremental change in one unit of BASDAI (0--100 scale) was estimated to be associated with a direct medical cost increase according to Cost = *£*708.45 + *£*75.00\*BASDAI \[[@B51]\]. For the Norwegian situation, no such information was available. As a result, the cost savings of treatment of AS have probably been underestimated, especially for etoricoxib.

This evaluation was performed for the Norwegian local situation. In general, it is difficult to "transfer" cost-effectiveness estimates obtained for one country to another, due to differences in treatment practices, resource use, and unit cost data, among other. Although the cost-effectiveness findings in this study were primarily driven by differences in efficacy of the compared interventions, the cost-effectiveness of the different NSAIDs for the management of ankylosing spondylitis in other countries needs to be confirmed with country-specific analysis.

In conclusion, given the underlying assumptions and current evidence available, this economic evaluation demonstrated that etoricoxib is a cost-saving and QALY gaining therapy for AS in Norway from a health care perspective.
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###### 

Transitions between different health states of Markov model due to events and lack of efficacy.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                           To                                                                                                                                                                                                                                                                                                                                  
  ---------------------------------------- ------------------------ ------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------- ------------------
  Initial NSAID                            \(i\) No events\         \(i\) Suspected PUB\            \(i\) Edema, hypertension, hepatic, CHF, renal; all with switching treatment\   Upper GI PUB                                                                CV event                       NA                                                                              NA
                                           (ii) Events w/o switch   (ii) Minor upper GI symptoms    (ii) Lack of efficacy                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                               

  Initial NSAID with PPI                   NA                       \(i\) Suspected PUB\            NA                                                                              \(i\) Upper GI\                                                             CV event                       NA                                                                              NA
                                                                    (ii) Minor upper GI symptoms\                                                                                   (ii) PUB Edema, hypertension, hepatic, CHF, renal; all with switching tx\                                                                                                                  
                                                                    (iii) No events\                                                                                                (iii) Lack of efficacy                                                                                                                                                                     
                                                                    (iv) Events w/o switch                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                               

  Alternative nsNSAID                      NA                       NA                              \(i\) No events\                                                                \(i\) Suspected PUB\                                                        CV event                       \(i\) Upper GI PUB\                                                             NA
                                                                                                    (ii) Events w/o switch                                                          (ii) Minor upper GI symptoms                                                                               (ii) Edema, hypertension, hepatic, CHF, renal; all with switching treatment\    
                                                                                                                                                                                                                                                                                               (iii) Lack of efficacy                                                          

                                                                                                                                                                                                                                                                                                                                                                               

  Alternative nsNSAID with PPI             NA                       NA                              NA                                                                              \(i\) Suspected PUB\                                                        CV event                       \(i\) Upper GI PUB\                                                             NA
                                                                                                                                                                                    (ii) Minor upper GI symptoms\                                                                              (ii) Edema, hypertension, hepatic, CHF, renal; all with switching treatment\    
                                                                                                                                                                                    (iii) No events\                                                                                           (iii) Lack of efficacy                                                          
                                                                                                                                                                                    (iv) Events w/o switch                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                               

  Alternative nsNSAID with PPI & aspirin   NA                       NA                              NA                                                                              NA                                                                          Suspected PUB\                 \(i\) Upper GI PUB\                                                             NA
                                                                                                                                                                                                                                                                (i) Minor upper GI symptoms\   (ii) CV event\                                                                  
                                                                                                                                                                                                                                                                (ii) No events\                (iii) Edema, hypertension, hepatic, CHF, renal; all with switching treatment\   
                                                                                                                                                                                                                                                                (iii) Events w/o switch        (iv) Lack of efficacy                                                           

                                                                                                                                                                                                                                                                                                                                                                               

  Anti-TNF*α*                              NA                       NA                              NA                                                                              NA                                                                          NA                             Other                                                                           Lack of efficacy

                                                                                                                                                                                                                                                                                                                                                                               

  Discontinued\                            NA                       NA                              NA                                                                              NA                                                                          NA                             NA                                                                              All
  anti-TNF*α*                                                                                                                                                                                                                                                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Individual studies and results included for mixed treatment comparison of BASFI, BASDAI and discontinuation due to lack of efficacy.

                                                           Placebo   Celecoxib   Naproxen\*   Etoricoxib   Diclofenac\*                                                         
  -------------------------------------------------------- --------- ----------- ------------ ------------ -------------- -------- -------- -------- -------- -------- -------- --------
  BASFI                                                                                                                                                                         
                                                                                                                                                                                
  Barkhuizen et al. \[[@B25]\]                             2.00      (3.00)      −9.00        (0.50)       −11.00         (1.00)   −16.00   (2.00)                              
  Van der Heijde et al. \[[@B16]\]                         −4.00     (1.90)                                                        −14.60   (1.80)   −19.40   (1.80)            
  Dougados et al. \[[@B26]\]                               1.30      (2.03)      −11.90       (2.46)                                                                            
  Sieper et al. \[[@B17]\]                                                       −8.00        (1.62)       −9.00          (1.23)                                       −9.00    (1.45)
                                                                                                                                                                                
  BASDAI                                                                                                                                                                        
                                                                                                                                                                                
  Van der Heijde et al. \[[@B16]\]                         −6.40     (1.90)                                                        −23.6    (1.80)   −28.60   (1.80)            
  Sieper et al. \[[@B17]\]                                                       −9.90        (1.71)       −13.20         (1.40)                                       −14.80   (1.41)
                                                                                                                                                                                
  Discontinuation for lack of efficacy and (sample size)                                                                                                                        
                                                                                                                                                                                
                                                           *r*       *n*         *r*          *n*          *r*            *n*      *r*      *n*      *r*      *n*      *r*      *n*
                                                                                                                                                                                
  Barkhuizen et al. \[[@B25]\]                             59        156         25           137          23             161      17       157                                 
  Van der Heijde et al. \[[@B16]\]                         44        93                                                            20       97       8        100               
  Dougados et al. \[[@B26]\]                               31        76          18           80                                                                                

\*For mixed treatment comparison of BASDAI, the results of naproxen and diclofenac were considered as the group nsNSAID.

###### 

Parameters (and distributions) for cost-effectiveness evaluation.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                          Value     Uncertainty range/95% credible interval   Assumed uncertainty distribution                                                                                                                                                                                                                         Source
  ------------------------------------------------------------------ --------- ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Efficacy*                                                                                                                                                                                                                                                                                                                                                                      

  Change from baseline BASFI                                                                                                                                                                                                                                                                                                                                                      

   Etoricoxib (90 mg)                                                −17.87    −22.16; −13.64                            No distribution assumed; posterior distributions directly obtained from mixed treatment comparison of extracted data and simultaneously forwarded into Markov model. For MTC, noninformative prior distributions were used.                              Barkhuizen et al. \[[@B25]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Van der Heijde et al. \[[@B16]\]\
                                                                                                                                                                                                                                                                                                                                                                                  Dougados et al. \[[@B26]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Sieper et al. \[[@B17]\]

   Celecoxib (200 mg)                                                −10.12    −12.34; −7.932                                                                                                                                                                                                                                                                                     

   Celecoxib (400 mg)                                                −11.8     −14.52; −9.10                                                                                                                                                                                                                                                                                      

   Diclofenac                                                        −11.51    −15.68; −7.34                                                                                                                                                                                                                                                                                      

   Naproxen                                                          −14.82    −17.69; −11.98                                                                                                                                                                                                                                                                                     

  Change from baseline BASDAI                                                                                                                                                                                                                                                                                                                                                     

   Etoricoxib (90 mg)                                                −28.53    −32.06; −25.05                            Van der Heijde et al. \[[@B16]\];\                                                                                                                                                                                                                       
                                                                                                                         Sieper et al. \[[@B17]\]                                                                                                                                                                                                                                 

   Celecoxib (200 mg)                                                −18.47    −24.12; −12.9                                                                                                                                                                                                                                                                                      

   Celecoxib (400 mg)                                                −21.77    −26.95; −16.51                                                                                                                                                                                                                                                                                     

   Diclofenac/naproxen                                               −23.46    −26.96; −19.96                                                                                                                                                                                                                                                                                     

  Probability of discontinuation                                                                                                                                                                                                                                                                                                                                                  

   Etoricoxib (90 mg)                                                0.063     0.027; 0.117                                                                                                                                                                                                                                                                                       

   Celecoxib (200 mg)                                                0.225     0.165; 0.292                              Barkhuizen et al. \[[@B25]\]                                                                                                                                                                                                                             

   Celecoxib (400 mg)                                                0.177     0.113; 0.255                              Van der Heijde et al. \[[@B16]\]                                                                                                                                                                                                                         

   Diclofenac/naproxen                                               0.149     0.105; 0.202                              Dougados et al. \[[@B26]\]                                                                                                                                                                                                                               

  BASFI without treatment                                            45        40; 50                                    Uniform (40, 50)                                                                                                                                                                                                                                         Based on baseline characteristics of trials included in MTC (see [Table 1](#tab1){ref-type="table"})

  BASDAI without treatment                                           45        40; 50                                    Uniform (40, 50)                                                                                                                                                                                                                                         

  Disease progression measured using annual changes in BASFI         0.5       0; 0.10                                   Uniform (0, 0.10)                                                                                                                                                                                                                                        Kobelt et al. \[[@B6]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Ara et al. \[[@B19]\]

  BASFI with anti-TNF*α*                                             23        20; 26                                    Uniform (20, 26)                                                                                                                                                                                                                                         Ara et al. \[[@B19]\]

  BASDAI with anti-TNF*α*                                            19        18; 20                                    Uniform (18, 20)                                                                                                                                                                                                                                         

  BASFI when stopped with anti-TNF*α*                                55        50; 60                                    Uniform (50, 60)                                                                                                                                                                                                                                         

  BASDAI when stopped with anti-TNF*α*                               52        47; 57                                    Uniform (47, 57)                                                                                                                                                                                                                                         

  Annual probability of discontinuation from anti-TNF*α* treatment   0.10      0.05; 0.15                                Beta (13.2, 118.8)                                                                                                                                                                                                                                       Ara et al. \[[@B19]\]

                                                                                                                                                                                                                                                                                                                                                                                  

  *Safety and treatment (annual probabilities)*                                                                                                                                                                                                                                                                                                                                   

  PUBs                                                                                                                                                                                                                                                                                                                                                                            

   Etoricoxib                                                        0.0111    0.0074; 0.0159                            No distribution assumed; posterior distribution directly obtained from indirect comparison analysis of extracted data and simultaneously forwarded into Markov model. For indirect comparison of safety, noninformative prior distributions were used.   Ramey et al. \[[@B11]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Silverstein et al. \[[@B14]\]

   Celecoxib                                                         0.0134    0.0075; 0.0221                                                                                                                                                                                                                                                                                     

   Diclofenac/naproxen                                               0.0270    0.0216; 0.0334                                                                                                                                                                                                                                                                                     

  Suspected PUBs                                                                                                                                                                                                                                                                                                                                                                  

   Etoricoxib                                                        0.0016    0.0000; 0.0061                            No distribution assumed; posterior distribution directly obtained from analysis of extracted data and simultaneously forwarded into Markov model. For indirect comparison of safety, noninformative prior distributions were used.                       Ramey et al. \[[@B11]\]

   Celecoxib                                                         0.0016    0.0000; 0.0061                                                                                                                                                                                                                                                                                     

   Diclofenac/naproxen                                               0.0030    0.0000; 0.0115                                                                                                                                                                                                                                                                                     

  Minor GI events                                                                                                        MEDAL study \[[@B15]\]                                                                                                                                                                                                                                   

   Etoricoxib/celecoxib                                              0.0463    0.0420; 0.0506                                                                                                                                                                                                                                                                                     

   Diclofenac/naproxen                                               0.0704    0.0650; 0.0759                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                  

  PUB risk reduction with PPI                                        0.40      ---                                       ---                                                                                                                                                                                                                                                      Moore et al. \[[@B28]\]

  Dying from PUB                                                     0.036     ---                                       ---                                                                                                                                                                                                                                                      Ramey et al. \[[@B11]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Laine et al. \[[@B27]\]

  Hospitalization given PUB                                          0.21      0.056; 0.358                              Uniform (0.056, 0.358)                                                                                                                                                                                                                                   Bloom et al. \[[@B38]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Maetzel et al. \[[@B39]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Knill-Jones et al. \[[@B40]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Singh and Ramey, \[[@B41]\];\
                                                                                                                                                                                                                                                                                                                                                                                  de Pouvourville \[[@B42]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Jönsson and Haglund, \[[@B43]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Gabriel and Matteson, \[[@B44]\],\
                                                                                                                                                                                                                                                                                                                                                                                  Smalley et al. \[[@B45]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Edelson et al. \[[@B46]\]

                                                                                                                                                                                                                                                                                                                                                                                  

  Surgery given hospitalization                                      0.25      0.12; 0.39                                Uniform (0.12, 0.39)                                                                                                                                                                                                                                     Maetzel et al. \[[@B39]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Knill-Jones et al. \[[@B40]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Jönsson and Haglund, \[[@B43]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Gabriel et al. \[[@B47]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Johnson et al. \[[@B48]\];\
                                                                                                                                                                                                                                                                                                                                                                                  Kong et al. \[[@B49]\]

  Inpatient tx given suspected PUB                                   0.25      0.18; 0.32                                Beta (36.5, 109.5)                                                                                                                                                                                                                                       Maetzel et al. \[[@B39]\]

  Treatment given minor GI                                           1         ---                                       ---                                                                                                                                                                                                                                                      Assumption

  Thrombotic CV event rate                                                                                               No distribution assumed; posterior distribution directly obtained from indirect comparison analysis of extracted data and simultaneously forwarded into Markov model. For indirect comparison of safety, noninformative prior distributions were used.   

   Etoricoxib                                                        0.0124    0.0111; 0.01381                           Cannon et al. \[[@B15]\];\                                                                                                                                                                                                                               
                                                                                                                         Curtis et al. \[[@B29]\]                                                                                                                                                                                                                                 

   Celecoxib                                                         0.0124    0.0111; 0.01381                                                                                                                                                                                                                                                                                    

   Diclofenac                                                        0.0131    0.0117; 0.01454                                                                                                                                                                                                                                                                                    

   Naproxen                                                          0.0077    0.0039; 0.01381                                                                                                                                                                                                                                                                                    

  Death from thrombotic CV event                                                                                                                                                                                                                                                                                                                                                  Cannon et al. \[[@B15]\]

   Etoricoxib/celecoxib                                              0.13      ---                                       ---                                                                                                                                                                                                                                                      

   Diclofenac/naproxen                                               0.128     ---                                       ---                                                                                                                                                                                                                                                      

  Edema                                                                                                                                                                                                                                                                                                                                                                           MEDAL \[[@B15]\]

   Etoricoxib/celecoxib                                              0.0106    0.0086; 0.0127                            Beta (101.4, 9459.7)                                                                                                                                                                                                                                     

   Diclofenac/naproxen                                               0.0070    0.0054; 0.0088                            Beta (64.9, 9165.4)                                                                                                                                                                                                                                      

  Hypertension                                                                                                                                                                                                                                                                                                                                                                    

   Etoricoxib/celecoxib                                              0.0229    0.0200; 0.0260                            Beta (218.9, 9342.0)                                                                                                                                                                                                                                     

   Diclofenac/naproxen                                               0.0153    0.0129; 0.0179                            Beta (141.2, 9088.8)                                                                                                                                                                                                                                     

  Coronary heart failure                                                                                                                                                                                                                                                                                                                                                          

   Etoricoxib/celecoxib                                              0.0044    0.0032; 0.0058                            Beta (42.1, 9518.9)                                                                                                                                                                                                                                      

   Diclofenac/naproxen                                               0.0026    0.0017; 0.0037                            Beta (24.7, 9490.5)                                                                                                                                                                                                                                      

  Hepatic events                                                                                                                                                                                                                                                                                                                                                                  

   Etoricoxib/celecoxib                                              0.0036    0.0025; 0.00489                           Beta (34.4, 9526.6)                                                                                                                                                                                                                                      

   Diclofenac/naproxen                                               0.0218    0.0189; 0.0249                            Beta (201.2, 9028.8)                                                                                                                                                                                                                                     

  Renal events                                                                                                                                                                                                                                                                                                                                                                    

   Etoricoxib/Celecoxib                                              0.0114    0.0094; 0.0136                            Beta (109.0, 9452.0)                                                                                                                                                                                                                                     

   Diclofenac/Naproxen                                               0.0100    0.0081; 0.0120                            Beta (92.3, 9137.7)                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                  

  *Utility*                                                                                                                                                                                                                                                                                                                                                                       

  Relation between EQ-5d and BASFI and BASDAI                                                                                                                                                                                                                                                                                                                                     Ara et al. \[[@B19]\]

   Constant                                                          0.924     0.890; 0.957                              Normal (0.924, 0.017^2^)                                                                                                                                                                                                                                 

   BASFI                                                             −0.004    −0.0057; −0.0029                          Normal (−0.004, 0.0007^2^)                                                                                                                                                                                                                               

   BASDAI                                                            −0.004    −0.0056; −0.0024                          Normal (−0.004, 0.0008^2^)                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                  

  *Disutility due to adverse events (adjusted for duration)*                                                                                                                                                                                                                                                                                                                      

  Surgery for PUB                                                    0.080     0.069; 0.092                              Beta distributions                                                                                                                                                                                                                                       Moore et al. \[[@B28]\]

  Inpatient treatment for PUB                                        0.062     0.052; 0.072                                                                                                                                                                                                                                                                                       

  Outpatient treatment for PUB                                       0.051     0.042; 0.060                                                                                                                                                                                                                                                                                       

  Inpatient investigation for suspected PUB                          0.062     0.052; 0.072                                                                                                                                                                                                                                                                                       

  Outpatient investigation for suspected PUB                         0.025     0.021; 0.030                                                                                                                                                                                                                                                                                       

  Minor GI symptoms requiring treatment                              0.015     0.012; 0.019                                                                                                                                                                                                                                                                                       

  Minor GI symptoms not requiring treatment                          0.00004   0.00000; 0.00032                                                                                                                                                                                                                                                                                   

  Thrombotic CV event                                                0.294     0.256; 0.331                              Moore et al. \[[@B28]\]                                                                                                                                                                                                                                  

  Edema                                                              0.020     0.016; 0.024                              Revicki \[[@B32]\]                                                                                                                                                                                                                                       

  Hypertension                                                       0.001     0.000; 0.002                              Stason and Weinstein, \[[@B33]\]                                                                                                                                                                                                                         

  Hepatic                                                            0.055     0.040; 0.072                              Nichol et al. \[[@B34]\]                                                                                                                                                                                                                                 

  CHF                                                                0.002     0.001; 0.002                              Wong et al, \[[@B35]\]                                                                                                                                                                                                                                   

  Renal                                                              0.020     0.016; 0.024                              Revicki \[[@B32]\]                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                  

  *Costs of events (NOK)*                                                                                                                                                                                                                                                                                                                                                         

  Surgery for PUB                                                    22,904    18,900; 27,300                                                                                                                                                                                                                                                                                     

  Inpatient treatment for PUB                                        22,904    18,900; 27,300                                                                                                                                                                                                                                                                                     

  Outpatient treatment for PUB                                       2,231     2,038; 2,437                              Gamma distributions                                                                                                                                                                                                                                      Resource use from Jansen et al. \[[@B50]\]; drug acquisition costs from NoMA (September 2007); GP costs from Norwegian Medical Association; DRG prices from ISF 2007 \[[@B36]\];

  Inpatient investigation for suspected PUB                          22,295    18,240; 26,700                                                                                                                                                                                                                                                                                     

  Outpatient investigation for suspected PUB                         1,297     1,157; 1,445                                                                                                                                                                                                                                                                                       

  Minor GI symptoms requiring treatment                              568       507; 636                                                                                                                                                                                                                                                                                           

  Thrombotic CV event                                                95,555    ---                                       ---                                                                                                                                                                                                                                                      NoMA (September 2007); ISF 2007 \[[@B36]\];

  CHF                                                                45,958    ---                                       ---                                                                                                                                                                                                                                                      NoMA (September 2007); ISF 2007 \[[@B36]\];

                                                                                                                                                                                                                                                                                                                                                                                  

  *Annual drug costs (NOK)*                                                                                                                                                                                                                                                                                                                                                       

  Etoricoxib (90 mg)                                                 4,654     ---                                       ---                                                                                                                                                                                                                                                      NoMA (September 2007)

  Celecoxib (200 mg)                                                 3,318     ---                                       ---                                                                                                                                                                                                                                                      

  Celecoxib (400 mg)                                                 6,636     ---                                       ---                                                                                                                                                                                                                                                      

  Diclofenac (150 mg)                                                1,588     ---                                       ---                                                                                                                                                                                                                                                      

  Naproxen (1000 mg)                                                 1,380     ---                                       ---                                                                                                                                                                                                                                                      

  PPI (omeprazole)                                                   3,050     ---                                       ---                                                                                                                                                                                                                                                      

  Aspirin (75 mg)                                                    383       ---                                       ---                                                                                                                                                                                                                                                      

  Anti-TNF*α* tx cost                                                143,322   ---                                       ---                                                                                                                                                                                                                                                      NoMA (September 2007)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Estimated effects and costs by treatment (base-case scenario).

                                      Etoricoxib (90 mg)   Celecoxib (200 & 400 mg)   Diclofenac (150 mg)   Naproxen (1000 mg)                                                                                     
  ----------------------------------- -------------------- -------------------------- --------------------- -------------------- ------------- ----------- ------------- ----------- --------- --------- --------- ---------
  *Life years*                                                                                                                                                                                                     
  1 yrs                               1                    1                          1                     1                    1             1           1             1           1         1         1         1
  5 yrs                               4.59                 4.59                       4.60                  4.59                 4.59          4.60        4.59          4.59        4.59      4.59      4.59      4.60
  30 yrs                              16.72                16.69                      16.76                 16.76                16.73         16.79       16.73         16.69       16.76     16.76     16.71     16.80
  *QALYs*                                                                                                                                                                                                          
  1 yrs                               0.74                 0.66                       0.80                  0.67                 0.59          0.75        0.69          0.61        0.76      0.70      0.62      0.77
  5 yrs                               3.34                 3.02                       3.64                  3.14                 2.78          3.48        3.17          2.82        3.50      3.22      2.88      3.54
  30 yrs                              11.16                9.85                       12.42                 10.66                9.24          12.04       10.71         9.30        12.08     10.80     9.41      12.15
                                                                                                                                                                                                                   
  *P* (best)^2^                       98.90%               at 1 year                  0.00%                 at 1 year            0.13%         at 1 year   0.98%         at 1 year                                 
  98.94%                              at 5 years           0.00%                      at 5 years            0.11%                at 5 years    0.95%       at 5 years                                              
  99.96%                              at 30 years          0.00%                      at 30 years           0.00%                at 30 years   0.04%       at 30 years                                             
                                                                                                                                                                                                                   
  *Treatment cost (NOK)*                                                                                                                                                                                           
  1 yrs                               4,654                4,654                      4,654                 4,977                4,977         4,977       1,588         1,588       1,588     1,380     1,380     1,380
  5 yrs                               50,020               41,400                     62,060                74,940               62,790        89,160      60,250        44,380      80,180    59,030    43,100    79,000
  30 yrs                              628,200              463,300                    823,600               740,500              544,400       971,100     710,400       517,500     937,800   708,900   516,200   936,000
                                                                                                                                                                                                                   
  *GI event costs (NOK)*                                                                                                                                                                                           
  1 yrs                               109                  69                         158                   124                  65            214         236           144         341       236       144       341
  5 yrs                               554                  360                        784                   648                  391           977         939           576         1,356     943       579       1,361
  30 yrs                              1,159                743                        1,644                 1,069                654           1,579       1,453         873         2,148     1,469     881       2,173
                                                                                                                                                                                                                   
  *Thrombotic CV event costs (NOK)*                                                                                                                                                                                
  1 yrs                               1,148                1,027                      1,278                 1,148                1,027         1,278       1,208         1,082       1,345     714       360       1,271
  5 yrs                               5,065                4,617                      5,542                 4,871                4,476         5,289       5,081         4,535       5,672     3,654     2,590     5,309
  30 yrs                              10,060               8,452                      11,650                7,696                6,712         8,756       8,293         6,852       9,920     6,541     4,888     8,833
                                                                                                                                                                                                                   
  *Other AE costs (NOK)*                                                                                                                                                                                           
  1 yrs                               202                  146                        268                   202                  146           268         120           77          171       120       77        171
  5 yrs                               814                  612                        1,048                 723                  555           918         502           323         718       504       324       720
  30 yrs                              1,507                1,098                      1,991                 1,048                795           1,342       820           513         1,201     828       517       1,214
                                                                                                                                                                                                                   
  *Total costs (NOK)*                                                                                                                                                                                              
  1 yrs                               6,115                5,974                      6,267                 6,452                6,300         6,618       3,152         2,981       3,332     2,449     2,073     3,015
  5 yrs                               56,450               47,920                     68,450                81,190               69,120        95,230      66,780        51,010      86,440    64,130    48,120    84,220
  30 yrs                              640,900              476,900                    835,600               750,300              554,500       980,800     721,000       528,800     947,700   717,800   526,000   944,700
                                                                                                                                                                                                                   
  *P* (best)^2^                       0.00%                at 1 year                  0.00%                 at 1 year            1.15%         at 1 year   98.85%        at 1 year                                 
  85.26%                              at 5 years           0.00%                      at 5 years            0.18%                at 5 years    14.57%      at 5 years                                              
  98.92%                              at 30 years          0.01%                      at 30 years           0.03%                at 30 years   1.04%       at 30 years                                             

^1^All results are discounted, 4.0% for effects and costs.

^2^Probability that a certain intervention provides best outcomes (i.e., greatest QALYs, lowest costs).

###### 

Cost-effectiveness of etoricoxib relative to other interventions (base-case scenario).

                                                       Incremental costs in NOK   Incremental QALYs   Incremental cost-effectiveness ratio                                              
  ---------------------------------------------------- -------------------------- ------------------- -------------------------------------- ------ ------ ------ ---------- ---------- ----------
  *1 year*                                                                                                                                                                              
  Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)   −337                       −411                −280                                   0.06   0.03   0.10   Dominant   Dominant   Dominant
  Etoricoxib (90 mg) versus diclofenac                 2,964                      2,753               3,173                                  0.05   0.02   0.09   59,221     33,180     184,500
  Etoricoxib (90 mg) versus naproxen                   3,666                      3,109               4,046                                  0.03   0.01   0.07   107,256    51,320     494,300
                                                                                                                                                                                        
  *5 years*                                                                                                                                                                             
  Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)   −24,730                    −37,730             −11,720                                0.20   0.08   0.33   Dominant   Dominant   Dominant
  Etoricoxib (90 mg) versus diclofenac                 −10,320                    −26,070             2,840                                  0.17   0.05   0.30   Dominant   Dominant   Dominant
  Etoricoxib (90 mg) versus naproxen                   −7,682                     −23,540             5,729                                  0.12   0.02   0.23   Dominant   Dominant   Dominant
                                                                                                                                                                                        
  *30 years*                                                                                                                                                                            
  Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)   −109,400                   −198,700            −38,640                                0.51   0.25   0.84   Dominant   Dominant   Dominant
  Etoricoxib (90 mg) versus diclofenac                 −80,060                    −164,800            −13,280                                0.45   0.20   0.76   Dominant   Dominant   Dominant
  Etoricoxib (90 mg) versus naproxen                   −76,850                    −162,100            −9,622                                 0.36   0.13   0.66   Dominant   Dominant   Dominant

###### 

Cost-effectiveness of etoricoxib relative to other interventions when anti-TNF*α* costs are set to zero.

                                                       Incremental costs in NOK   Incremental QALYs   ICER                                                
  ---------------------------------------------------- -------------------------- ------------------- -------- ------ ------ ------ ---------- ---------- ----------
  *1 year*                                                                                                                                                
  Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)   −337                       −410                −280     0.06   0.03   0.10   Dominant   Dominant   Dominant
  Etoricoxib (90 mg) versus diclofenac                 2,965                      2,756               3,173    0.05   0.02   0.09   59,288     33,190     188,200
  Etoricoxib (90 mg) versus naproxen                   3,663                      3,099               4,043    0.03   0.01   0.07   107,074    50,970     488,500
  *5 years*                                                                                                                                               
  Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)   2,194                      426                 3,745    0.20   0.08   0.33   10,926     2083       30820
  Etoricoxib (90 mg) versus diclofenac                 10,560                     9,058               11,880   0.17   0.05   0.30   62,411     34650      198400
  Etoricoxib (90 mg) versus naproxen                   12,370                     10,330              14,000   0.12   0.02   0.23   103,083    49220      465100
  *30 years*                                                                                                                                              
  Etoricoxib (90 mg) versus celecoxib (200 & 400 mg)   15,740                     5,398               25,490   0.51   0.25   0.84   31,009     14330      59810
  Etoricoxib (90 mg) versus diclofenac                 23,910                     14,520              32,990   0.45   0.20   0.76   53,181     34020      103800
  Etoricoxib (90 mg) versus naproxen                   25,660                     16,150              34,810   0.36   0.13   0.66   70,825     42830      170900

[^1]: Academic Editor: Ruben Burgos-Vargas
